EIDX

EIDX

Last Updated:

Q3 '20

Eidos Therapeutics

Eidos is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need caused by transthyretin (TTR) amyloidosis (ATTR).

Cash

$147.3M

Burn Rate (Qtr)

$30.2M

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

ATTRibute-PN

Transthyretin amyloidosis (ATTR)

Pase 3 Initiation

2H 2020

ATTRibute-CM

Transthyretin amyloidosis (ATTR)

Phase 3 top-line data

H2 2021

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon